Connect
Mayo Doing Bronchiectasis Research - ongoing
Hello Group, I just returned from my bi-annual Mayo (Rochester) check up. I was contacted by one of Mayo's research coordinators before I went down and I met with her on my last day. They are still in need of about 300 (min) more volunteers. This research has been going on since 2008(?) I asked why they don't have the 1000 volunteers yet after so many years and she said they can't "advertise" but can only ask those who are scheduled for an appointment. So, the research has been slow. I told her I would be happy to post in the chat here and see if I could drum up some interest.
If you are interested in joining the research you can contact Jennifer McNamara at - McNamara.Jennifer2@mayo.edu or call her
at 507-266-6705. She can explain the research and you don't need to be present to participate.
I joined because I am really interested in pushing this Sisyphus rock over the other side of the hill. I have had MAC/Bronchiectasis for over a decade.
Thanks a million and please feel free to contact her.
From the research intake sheet that I received and signed -
"Study participation involves letting us collect and store clinical information (including imaging studies) that have been or will be obtained by Mayo. The research team will update the information collected on an annual basis to reflect your current health status as long as you choose to stay enrolled in the Registry. This will not require that you come for a visit to the research center."
Key Information - "This information will be stored and used by Mayo and other members of the registry. For your protection, all imaging studies and information will be coded with a unique code and will not contain any information that will identify you unless consented to and necessary for database linkage."
Like
Helpful
HugInterested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.
Connect
Would it be possible to say more about the nature of the research? Maybe a link with more info?
-
Like -
Helpful -
Hug
1 ReactionI just added that info to the original post. Thank you
I am part of a research study on bronchiectasis through Dr. Honda at NJH. I am seen at the UT East Texas Pulmonary Clinic in Tyler TX.
What I am really interested in is besides a bronchiectasis research is any research trials on ways to combat the biofilm that protects the acid fast microbacterium. I have abscesses subsp abscessus along with bronchiectasis. If anyone knows of any research studies who are looking for trial participants to combat biofilm, I am interested in participating.
Nancy
Clinical Trials on Anti-Biofilm Approaches Against Mycobacteria
1. CMTX-101 – a Biofilm-Disrupting Monoclonal Antibody
A clinical trial listed on ClinicalTrials.gov is evaluating CMTX‑101, a monoclonal antibody designed to disrupt bacterial biofilms as an adjunct to standard antibiotic treatment. Though the trial mentions “bacterial biofilm,” it does not explicitly specify Mycobacterium exposure in the publicly available summary. 
2. Preclinical Research (Animal Models)
• Monoclonal Antibody Targeting Mycobacterium abscessus Biofilms
In preclinical (murine) studies, researchers developed an epitope-targeted monoclonal antibody capable of rapidly dismantling biofilms formed by Mycobacterium abscessus, substantially reducing bacterial load and inflammation. 
• Small Molecule Compounds (e.g., NF1001)
Studies have highlighted novel compounds like NF1001, a thiopeptide antibiotic with potent activity against both planktonic M. abscessus and M. avium as well as their biofilm forms. 
• DNABII-Targeting Antibody (‘HuTipMab’)
Experimental investigations into biofilms of nontuberculous mycobacteria (NTM) have explored a humanized DNABII-targeted monoclonal antibody (HuTipMab) for its ability to disrupt biofilm matrices. 
These studies are promising, but they remain preclinical and haven’t progressed to national-level clinical trials yet.
⸻
Broader Landscape: NTM Clinical Trials (Internal Focus)
A 2024 review surveyed clinical trials for NTM (non-tuberculous mycobacteria) therapies on ClinicalTrials.gov. The majority of these trials are focused on:
• Optimizing existing antibiotic combinations (e.g., amikacin, azithromycin, clofazimine, bedaquiline, linezolid)
• Dosage or regimen refinements for guideline-based therapy
However, the review found no indication that current trials are testing strategies specifically targeting biofilm disruption.  
-
Like -
Helpful -
Hug
5 ReactionsClinical Trial
CMTX‑101 (monoclonal antibody)
Biofilm disruption—unspecified pathogen, possibly bacterial in general
Preclinical
Epitope-targeted monoclonal Abs (murine)
M. abscessus biofilms in animal models
Preclinical
NF1001 (thiopeptide antibiotic)
Effective against M. avium/M. abscessus biofilms
Preclinical
HuTipMab (DNABII-targeted antibody)
NTM biofilm disruption
Internal NTM Trials
Antibiotic regimen optimization
Final Take
• No large-scale, nationwide clinical trials are currently documented that specifically target biofilm disruption in Mycobacterium infections.
• CMTX-101 is the only clinical-stage candidate that targets biofilm disruption, but it’s not confirmed to include Mycobacterium as its intended pathogen.
• Preclinical research is actively developing biofilm-targeted strategies—such as monoclonal antibodies and novel antimicrobials—but these are not yet in human trials.
-
Like -
Helpful -
Hug
1 ReactionI will contact my doctors at UT east texas in Tyler Pulmonary Clinic to get their opinions if a trial might be possible for me to enter. I do really well on my triple IV antibiotics against the obsesses first MASSILIENCE and now obsessive obsessive two years apart. I am taking the same IV antibiotics( Impenimum/Cilastatin, Tygecycline and Amikacin). I converted quickly in 2023- massilience- we will see how I do with the abscesses subsp Abscessus now. Thanks again .
Nancy
Abscessus subsp. Abscessus not obsessive obsessive. ::(